Romidepsin (FK228, Depsipeptide)

目录号:S3020 别名: FR 901228, NSC 630176

Romidepsin (FK228, Depsipeptide) Chemical Structure

Molecular Weight(MW): 540.7

Romidepsin (FK228, Depsipeptide)是一种有效的HDAC1HDAC2抑制剂,无细胞试验中IC50分别为36 nM和47 nM。

规格 价格 库存 购买数量  
RMB 1285.83 现货
RMB 3910.79 现货
RMB 5710.89 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用该产品的3个实验数据:

  • An HIV-Gag-SLYNTVATL-specific CTL clone was labeled with Alexa-Fluor555 conjugated cholera toxin subunit B either cultured with 500 nM SAHA or 25 nM romidepsin for 20 hours, or maintained as an untreated control. These effector cells were combined with SLYNTVATL peptide pulsed target cells, matched on the restricting allele, in a collagen matrix medium containing sytox green viability dye. These mixtures were then plated in three separate wells of an 8-well cover slip and imaged by time-lapse brightfield and fluorescent microscopy. A. Shown are representative fields of view from the no treatment (upper panel), 500 nM SAHA (middle panel), and 25 nM romidepsin (lower panel) conditions advancing in time from left to right. Time stamps are given in hh[ratio]mm format. Clones described in the results are indicated with yellow arrows and killed target cells are indicated with white arrows in the upper right panel.

    PLoS Pathog 2014 10(8), e1004287. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

    PLZF-RARa–nonexpressing and -expressing PLZFRARβ3 cells were treated with 5 nmol/L romidepsin for the indicated time points. Induction of the DNA DSB marker γH2AX was measured by Western blotting. β-Actin was used as a loading control.

    Mol Cancer Ther 2013 12(8), 1591-604. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

  • Effects of combination of bort/romidepsin on HDAC6 inhibition and activation of ER stress signaling. HA cells were treated with combination of 15 nM bortezomib and 5 nM romidepsin or either drug alone for 24 hr. Expression of CHOP/GADD153 (green signals) and cleaved PARP (red signals) was detected by immunofluorescent staining. DAPI (blue signals) stained the cell nuclei.

    Int J Cancer 2014 135(12):2950-61. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

产品安全说明书

HDAC抑制剂选择性比较

生物活性

产品描述 Romidepsin (FK228, Depsipeptide)是一种有效的HDAC1HDAC2抑制剂,无细胞试验中IC50分别为36 nM和47 nM。
特性 Romidepsin对I型HDAC的抑制作用明显强于对II型HDAC的抑制。
靶点
HDAC1 [1]
(Cell-free assay)
HDAC2 [1]
(Cell-free assay)
36 nM 47 nM
体外研究

Romidepsin抑制NSCLC细胞系生长,IC50范围从1.3 ng/mL到4.9 ng/mL。 Romidepsin可以降低Erlotinib对NSCLC细胞系的IC50值, 增加NSCLC细胞系对Erlotinib的敏感性[1]。Romidepsin处理72小时可以抑制6/6 人 NB 肿瘤细胞系的生长,而 NIH3T3细胞系并不受影响。 Romidepsin对于单拷贝或N-myc 多拷贝的NB细胞系以及含有正常或突变的p53 和含有Alk突变体的细胞系都有选择性的细胞毒性,这种毒性具有剂量依赖的特性。[2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SU-DHL4 NVy1U4tVS2WubDDWbYFjcWyrdImgRZN{[Xl? NY[5cmdkOi53LUG1JI5O MXi3NkBp NYXLPXpRcW6mdXPld{BkgXSxdH;4bYNqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?= MoT2NlU4QTB7MEe=
U2932  M3fqNWNmdGxiVnnhZoltcXS7IFHzd4F6 MYeyMlUuOTVibl2= NGjMbJE4OiCq NILhOoVqdmS3Y3XzJIN6fG:2b4jpZ4l1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi MXeyOVc6ODlyNx?=
OCI-LY7 MmrkR4VtdCCYaXHibYxqfHliQYPzZZk> MmPFNk42NTF3IH7N NWTCZY5uPzJiaB?= NV:1RXRKcW6mdXPld{BkgXSxdH;4bYNqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?= M{HWe|I2PzlyOUC3
Farage MXfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MY[yMlUuOTVibl2= M1\uSVczKGh? MmXUbY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? M2jYS|I2PzlyOUC3
LY7/EBV NWLhfZNiS2WubDDWbYFjcWyrdImgRZN{[Xl? MoXZNk42NTF3IH7N NIPwTXA4OiCq M3zDN4lv\HWlZYOgZ5l1d3SxeHnjbZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB? NVP6NWlqOjV5OUC5NFc>
U2932/EBV NGPwS45E\WyuIG\pZYJqdGm2eTDBd5NigQ>? MYeyMlUuOTVibl2= NFv3V3c4OiCq MX\pcoR2[2W|IHP5eI91d3irY3n0fUBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7lduKh MmS3NlU4QTB7MEe=
HCT116 Mln0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWe1MVUxODBibl2= NIjLOnIzPCCq NIDwUpZFVVOR MYLpcoR2[2W|IHPlcIwh\GWjdHigbY4h[SClb37j[Y51emG2aX;uMYRmeGWwZHXueEBu[W6wZYK= NVPmZYlrOjV2OUK1NVU>
ACH-2 MmLhSpVv[3Srb36gRZN{[Xl? MXqxMVkhdk1? Ml21NlQhcA>? MXHpcoR2[2W|IFjJWk0yKEWwdjDlfJBz\XO|aX;u NWTaTIsyOjVzNEm0Olc>
MCF-10A NHji[I1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjGTWM2OD1yLkG3xtExNjBzIH7N NF3aUVYzPDl3NEi1Oi=>
MCF-7 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHhSY5ZUUN3ME2xMlExyrFyLkKwJI5O M4DJRVI1QTV2OEW2
SK-BR-3 NYDLTFRRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;weI96UUN3ME2xMlAxyrFyLkO1JI5O NUmzSlQ{OjR7NUS4OVY>
MDA-MB-231 NXzVcnJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmO3TWM2OD1yLk[4xtExNjF2IH7N NVvo[W5mOjR7NUS4OVY>
PC3 NIm1TnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrYTWM2OD1zLk[1xtExNjN3IH7N M3PpWlI1QTV2OEW2
HCT116 MmjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF:2T4xKSzVyPUGuNFDDuTBwMECgcm0> M1S4[FI1QTV2OEW2
HCT116-p21-/- NXLBXIR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTFwMkdCtVAvOzdibl2= M3z5W|I1QTV2OEW2
S1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4noSWlEPTB;Nz62O:KyOC5{OTDuUS=> M3SxPVI1QTV2OEW2
SW620 M1nNXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfKTWM2OD1yLkmzxtExNjJ7IH7N NH[zSnIzPDl3NEi1Oi=>
LOX-IMVI NILMN5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDYOpFKSzVyPUCuPFfDuTBwMEOgcm0> MmSzNlQ6PTR6NU[=
UACC-62 NVPOZ|hrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTBwNUdCtVAvOTZibl2= NEPE[lgzPDl3NEi1Oi=>
MDA-MB-435 M1\RdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTBwOUFCtVAvODZibl2= Mo\ONlQ6PTR6NU[=
SF-295 M{nuZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\rPVFKSzVyPUCuPFjDuTBwMUWgcm0> NEDBRVAzPDl3NEi1Oi=>
A549 M4XJdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYX5d3V6UUN3ME2xMlI3yrFyLkK0JI5O MnOzNlQ6PTR6NU[=
H460 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTJwNUlCtVAvQDBibl2= NIn3e5YzPDl3NEi1Oi=>
EKVX NGPrWHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\UVWlEPTB;MT6zN:KyOC5|NDDuUS=> NEPKNWMzPDl3NEi1Oi=>
H146 NUX0e|VvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fJOmlEPTB;MD6yNuKyOC5yNzDuUS=> NYPaTHZSOjR7NUS4OVY>
H526 MnTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nLS2lEPTB;MD6xOeKyOC5yMzDuUS=> MlnSNlQ6PTR6NU[=
HuT-78 NU\PT3c5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTFwN{RCtVAvPDRibl2= NUSxc4NVOjR7NUS4OVY>
HA MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTPb5kxNjZ{NT2xNI5O M1WwRVQ5KGh? NU\tT|IzcW6mdXPld{BiKHOrZ37p[olk[W62bImgd5Rzd26pZYKgbY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25iY3:teJJm[XSnZDD3bZRpKGKxcoTlfo9ucWJ? NWX6WGNLOjR5N{G1NVA>
MS-275 NWHKVG8yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHJTHgxNjZ{NT2xNI5O MYm0PEBp MV3pcoR2[2W|IHGgd4lodmmoaXPhcpRtgSC|dILvcodmeiCrbnjpZol1cW:wIH;mJINmdGxicILvcIln\XKjdHnvckBkdy22cnXheIVlKHerdHigZo9zfGW8b33pZi=> NYW2UHZVOjR5N{G1NVA>
CD4 T NEDWW|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTCcmg1QCCq NUDIeIx6TUN3ME20MlXDuTFwMDDuUS=> M{DNOFI1PzJ{NEW0
CD4 T MoT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LicVQ5KGh? NUT0VopYS0N3ME2xNFfDuTF{NjDuUS=> NGnMSm0zPDd{MkS1OC=>
CD4+ T NUTESmF7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPvXoFXTUN3ME2zJI5O M4HUXlI1PDl3MUC1
A549 NUCyTIc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXBNVDjiJNzMEFCpI5O MV[yOE8{Pi92ODDo MnjhbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEBkd26lZX70doF1cW:wLTDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ NGr2Z5gzPDR6NUe5PS=>
JJN3 NXTDSoxTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\GNlQwPDhiaB?= MmnGSWM2ODxz4pEJcm08KDR64pEJbC=> MVeyOFA{ODF3MB?=
OPM-2 NHvNOlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUmyOE81QCCq MnTzSWM2OHN;MfMAjY5OQyB2OPMAjYg> NVL6d2JyOjRyM{CxOVA>
RPMI-8226 NVHBOIRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHBb3YzPC92ODDo NUC0eHVuTUN3MIO9NU456oDLbl27JFQ56oDLaB?= M4fCe|I1ODNyMUWw
U266 NFS1SIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7VZ|lKOjRxNEigbC=> MVPFR|Uxez1zMPMAjY5OQyB2OPMAjYg> NX3lOIo3OjRyM{CxOVA>
CA46 NUX1fIVkSXCxcITvd4l{KEG|c3H5 MWq2JIg> NFXET3dqdmS3Y3XzJIJtfW62IHHwc5B1d3Orcx?= MV[yN|k3PjF4NB?=
DG75 MXjBdI9xfG:|aYOgRZN{[Xl? NEfQVFc3KGh? MmDnbY5lfWOnczDuc{BieG:ydH;zbZM> NVzKfHZlOjN7Nk[xOlQ>
Ramos M1i0VGFxd3C2b4Ppd{BCe3OjeR?= NXTQRWJVPiCq NUTQUYZucW6mdXPld{BmgHSnboPpeoUh[XCxcITvd4l{ MljmNlM6PjZzNkS=
ST486 MYLBdI9xfG:|aYOgRZN{[Xl? MkXOOkBp M132eolv\HWlZYOg[Zh1\W6|aY\lJIFxd3C2b4Ppdy=> NICye40zOzl4NkG2OC=>
HuT78 MUfBdI9xfG:|aYOgRZN{[Xl? MVmxM|ExNzFyMDDuUS=> MkL1OFghcA>? MWnpcoR2[2W|IHHwc5B1d3OrczDheEAyKG6P M4fNb|I{PTN{N{Oy
DpVp35 MV3BdI9xfG:|aYOgRZN{[Xl? NWjUbGl3OS9zMD:xNFAhdk1? Ml3nOFghcA>? MWPpcoR2[2W|IHLseY51KGGyb4D0c5Nqew>? NEfIV3YzOzV|MkezNi=>
DpVp50 MYXBdI9xfG:|aYOgRZN{[Xl? NEnib3IyNzFyL{GwNEBvVQ>? MoHvOFghcA>? NHLxTJRqdmS3Y3XzJIJtfW62IHHwc5B1d3Orcx?= NF\ZUGszOzV|MkezNi=>
DpP75  M{DqPWFxd3C2b4Ppd{BCe3OjeR?= Mlu3NU8yOC9zMECgcm0> NFTqe4E1QCCq NIi1N3dqdmS3Y3XzJIJtfW62IHHwc5B1d3Orcx?= NECybY8zOzV|MkezNi=>
SKOV-3 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn[wNgKBmzJybl2= MoizO|IhcA>? NHSyTFVFVVOR NEnxNllz\WS3Y3XzJINmdGxidnnhZoltcXS7IHHsc45mKGGwZDDjc41jcW6nZDD3bZRpKGOrc4DsZZRqdg>? M3zlS|I{ODFyM{S4
Brca1 WT MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2ThO|HjiJN{MH7N NUPQfmJ1PzJiaB?= MVnEUXNQ NF;CR29z\WS3Y3XzJINmdGxidnnhZoltcXS7IHHsc45mKGGwZDDjc41jcW6nZDD3bZRpKGOrc4DsZZRqdg>? M{O2elI{ODFyM{S4
Brca1 Null NHHs[WNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnS0NgKBmzJybl2= M{Xnd|czKGh? NWjDSYhbTE2VTx?= NXvrS3pIemWmdXPld{Bk\WyuII\pZYJqdGm2eTDhcI9v\SCjbnSgZ49u[mmwZXSge4l1cCClaYPwcIF1cW5? M2npTlI{ODFyM{S4
OVCAR-8  NWTGboVLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDpbI4y6oDVMkDuUS=> M1XSfFczKGh? MVvEUXNQ NEX5VHZz\WS3Y3XzJINmdGxidnnhZoltcXS7IHHsc45mKGGwZDDjc41jcW6nZDD3bZRpKGOrc4DsZZRqdg>? NH3YUoQzOzBzMEO0PC=>
NCI/ADR-RES MlXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU[x5qCUOjCwTR?= MmPUO|IhcA>? NXHnZ3F3TE2VTx?= Ml7qdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCjbH;u[UBidmRiY3;tZolv\WRid3n0bEBkcXOybHH0bY4> MnPBNlMxOTB|NEi=
HCT116 MlTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LKTlUhdk1vNUCg{txO MmH0NlQhcA>? M2HvWGROW09? M4HvfolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz M3XJWlIzQTJ2OUW4
RKO MmfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfi[W42KG6PLUWwJO69VQ>? MVmyOEBp NVvBdHdsTE2VTx?= MlH1bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI> MnXaNlI6OjR7NUi=
CO115 M3S0XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTQRnlwPSCwTT21NEDPxE1? MlqzNlQhcA>? MXvEUXNQ Mke4bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI> NWXwbFB6OjJ7MkS5OVg>
HFS MnTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfyRmtzPSCwTR?= MlvqNlQwPDhxN{KgbC=> NX7QUYoycW6qaXLpeJMh[2WubDDndo94fGhidHnt[U1l\XCnbnTlcpRtgQ>? MoPENlIyODZ{OEK=
LNCaP MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnJOUBvVQ>? M{X2W|I1NzR6L{eyJIg> NGXrcodqdmirYnn0d{Bk\WyuIHfyc5d1cCC2aX3lMYRmeGWwZHXueIx6 M3;qT|IzOTB4Mkiy
A549 M4HoU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37HcVUhdk1? M1H0VVI1NzR6L{eyJIg> M4nYVIlvcGmkaYTzJINmdGxiZ4Lve5RpKHSrbXWt[IVx\W6mZX70cJk> M3vlcVIzOTB4Mkiy
697  Ml3pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2Wy[mlEPTEkgJm95qCKOi53wrDuUS=> NWf5XFZ4OjF3M{iyNVY>
697-R NFnUfXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|Ux6oDLPfMAjVgvPsLibl5CpC=> MmOwNlE2Ozh{MU[=
HUT78 M{nPXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTzTWM2OD1zIH7N M1[3XFIyOTl6NUS1
THJ-16T M{nwSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHEe2JzOSCwTR?= MX[yOEBp MWLpcohq[mm2czDj[YxtKGe{b4f0bC=> MX:yNFgyODV4OB?=
HCT116 MVjGeY5kfGmxbjDBd5NigQ>? Mn\0NlAhdk1? MnvZPEBp Ml7hcY9lfWyjdHXzJJRz[W6|Y4LpdJQhdGW4ZXzzJIZweiCqdX7kdoVleyCxZjDn[Y5meyCrbjDlbZRp\XJiZHny[YN1cW:w M1[0OlIxPzN7NEW0
B104  NVLL[m41TnWwY4Tpc44hSXO|YYm= M1;GPFIhdk1? MY[yOE81QC95MjDo NH\mSVJqdmO{ZXHz[ZMhfGinIIP1doZi[2ViZYjwdoV{e2mxbjDv[kBETDJywrC= MUmyNFY5PjVyNR?=
HL-60  NYPUXnNCS3m2b4TvfIlkcXS7IFHzd4F6 MXGxMVUxOCCwTR?= MX6yOEBp MnjPbY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? MoDVNlA3OjRzNkO=
HP100 MYjDfZRwfG:6aXPpeJkhSXO|YYm= MorENU02ODBibl2= NEPkVXIzPCCq MX;pcoR2[2W|IHP5eI91d3irY3n0fUBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7lduKh M3TTZ|IxPjJ2MU[z
HL-60  Ml23SpVv[3Srb36gRZN{[Xl? NFHQOnIyOCCwTR?= NFfOWlU1NzZxMU[gbC=> NVraUpk2cW6mdXPld{B1cGViZ3Xu[ZJifGmxbjDv[kBpgWS{b3flckBx\XKxeHnk[UBnem:vIETo MUSyNFYzPDF4Mx?=
HP100 MmfqSpVv[3Srb36gRZN{[Xl? NIjzNm4yOCCwTR?= MmLpOE83NzF4IHi= MnnBbY5lfWOnczD0bIUh\2WwZYLheIlwdiCxZjDofYRzd2enbjDw[ZJwgGmmZTDmdo9uKDSq MlTGNlA3OjRzNkO=
HL-60  M3zZbmZ2dmO2aX;uJGF{e2G7 NYnG[po1OTBvNUCwJI5O MnXWOEBp NGS1Tmhl\WO{ZXHz[ZMhfGinIHjpd5RwdmViZHXhZ4V1gWyjc3WgLGhFSUNrIHHjeIl3cXS7wrC= NU\ESJZLOjB4MkSxOlM>
HP100 M33DbWZ2dmO2aX;uJGF{e2G7 NH:1SFcyOC13MECgcm0> NEDLb2o1KGh? M4rYWYRm[3KnYYPld{B1cGViaHnzeI9v\SCmZXHj[ZR6dGG|ZTCoTGRCSyliYXP0bZZqfHoEoB?= MWmyNFYzPDF4Mx?=
11z M2TPNWtqdmG|ZTDBd5NigQ>? NVWyeJUxOy1zMECgcm0> NF;Y[oZz\WS3Y3XzJGhFSUNiZX76fY1ifGmlIHHjeIl3cXS7IDjJR|UxyqB;IE[uOUDDuSByLk[gco1wdC:OKR?= NXLoUoxFOjB4MEWxOFQ>
SKOV-3 NYXmd2F1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fyRVQwQC9zNjDuUS=> NV;kO2FMPDhiaB?= NWjtZllocW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XJ? NWr2bpNnOjB2MES1OlQ>
OVCAR-3 M1G3cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PuZ|QwQC9zNjDuUS=> NIfOfnc1QCCq NVL0RoN4cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XJ? Ml7VNlA1ODR3NkS=
HBL-2 NWfOc4RTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnIenlOOi1zMDDuUS=> NUDRcnIyOjRiaB?= M{nJcGlEPTB;ND6zJI5O NFG3UHUzODB4OEC4NC=>
Jeko-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXOyMVUxKG6P MXmyOEBp MWLJR|UxRTFzIH7N M1z0cFIxODZ6MEiw
Granta-519 NF7iUoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\XTWQ2NTRyIH7N NWPmR4w6OjRiaB?= MWPJR|UxRTV6LkWgcm0> MX2yNFA3QDB6MB?=
L1236 MUHDfZRwfG:6aXPpeJkhSXO|YYm= M4TDNVEhdk1vMUCwJO69VQ>? NYjLbZZkPDhiaB?= MnXwSWM2OD1yLkC3JO69VQ>? MWGxPVI{OzR5MB?=
L428 M3nLUGN6fG:2b4jpZ4l1gSCDc4PhfS=> MoT1NUBvVS1zMECg{txO NXPDWW1jPDhiaB?= NFzne|hGSzVyPUCuOFMh|ryP NG[4d3YyQTJ|M{S3NC=>
KM-H2 MVTDfZRwfG:6aXPpeJkhSXO|YYm= MVWxJI5ONTFyMDFOwG0> NV64eVk6PDhiaB?= NFfRWpBGSzVyPUCuOVgh|ryP MkG0NVkzOzN2N{C=
L540Cy M3fPU2N6fG:2b4jpZ4l1gSCDc4PhfS=> NHfDdnoyKG6PLUGwNEDPxE1? M1WwclQ5KGh? M1n2NmVEPTB;MD6xOkDPxE1? MUKxPVI{OzR5MB?=
G401 NVzMUmQ1TnWwY4Tpc44hSXO|YYm= MVuxNEBvVQ>? M2jzbVI1NzR6L{eyJIg> NIjaXGFFVVOR NYrNVXgycW6lcnXhd4V{KEOGS16xR{BmgHC{ZYPzbY9v MXWxPVIzOTV6Nh?=
STM91-01 MV3GeY5kfGmxbjDBd5NigQ>? NHzVbIgyOCCwTR?= MV6yOE81QC95MjDo MlexSG1UVw>? NHrrV|VqdmO{ZXHz[ZMhS0SNTkHDJIV5eHKnc4Ppc44> NVTldlQ3OTl{MkG1PFY>
SJSC  M1fuR2Z2dmO2aX;uJGF{e2G7 MmnDNVAhdk1? MoPsNlQwPDhxN{KgbC=> NETPPWNFVVOR MXXpcoNz\WG|ZYOgR2RMVjGFIHX4dJJme3Orb36= NWHBeGRQOTl{MkG1PFY>
BT16  NY\rNnhOTnWwY4Tpc44hSXO|YYm= NFW3UpUyOCCwTR?= MYWyOE81QC95MjDo MWDEUXNQ NYDxZZpScW6lcnXhd4V{KEOGS16xR{BmgHC{ZYPzbY9v NWXHdopIOTl{MkG1PFY>
NCI-H1299 M{fDemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTRwNtMxNE4zKG6pL33s NEn5fYMyQTF5OUi5NC=>
NCI-2882 MnKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV[0OY45UUN3ME2xMlbDuTBwMESgcocwdWx? NV;nTJc2OTlzN{m4PVA>
HCC95 Ml2xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHC[2tKSzVyPUKuOeKyOC5yNTDu[{9udA>? M4\CTFE6OTd7OEmw
NCI-H23 M17RVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLvOlhKSzVyPUKuPeKyOC5{IH7nM41t NULkcXB[OTlzN{m4PVA>
NCI-H157 Ml;xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYm5V2VoUUN3ME2xMlbDuTBwMEKgcocwdWx? Ml7ENVkyPzl6OUC=
NCI-H460 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTJwMdMxNE4xPyCwZz;tcC=> MkjzNVkyPzl6OUC=
NCI-H1975 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFe2W5BKSzVyPUGuN:KyOC5yNDDu[{9udA>? MUexPVE4QTh7MB?=
NCI-H820 NE\m[3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfpR2dKSzVyPUKuOOKyOC5zIH7nM41t NIf6RlgyQTF5OUi5NC=>
NCI-H1650 Mme5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfPVlhKSzVyPUSuPeKyOC5|IH7nM41t NFLkfI8yQTF5OUi5NC=>
DTC1 NV;YVWVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2e5SGlEPTB;MD61NUBvVQ>? NHzEb3AyQDV4NkK0Oi=>
KAO M4Hs[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{mwTmlEPTB;MD65NUBvVQ>? NEn5U2kyQDV4NkK0Oi=>
SU-CCS-1 MkD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnocY9lUUN3ME2wMlg6KG6P NH;nbGsyQDV4NkK0Oi=>
SYO-1 MofQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY[xcmh5UUN3ME2wMlY4KG6P NG\P[XUyQDV4NkK0Oi=>
FUJI M2XDfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfnTXVKSzVyPUGuN|Ehdk1? M1f4bVE5PTZ4MkS2
SKNMC MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LnNGlEPTB;MT6xO{BvVQ>? MXuxPFU3PjJ2Nh?=
402-91 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2O4fWlEPTB;MT6yOkBvVQ>? NXX5UnRkOTh3Nk[yOFY>
1765-92 M3vZNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjadHVXUUN3ME2xMlc4KG6P NEPxT5cyQDV4NkK0Oi=>
JN-DSRCT-1 MlPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrNcnNIUUN3ME2xMlI2KG6P MVixPFU3PjJ2Nh?=
NMS-2PC M1;XO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVu2WIhXUUN3ME2wMlgyKG6P NF\pTmwyQDV4NkK0Oi=>
HL60 NFTzdYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknGTWM2OD1zLki2JI5O MVuxPFU3PjJ2Nh?=
A549 NIXHd3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PrcGlEPTB;Mz6yOEBvVQ>? MnLNNVg2PjZ{NE[=
SW480 NH24b3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HyT2lEPTB;Mj62PUBvVQ>? NVn6[|N1OTh3Nk[yOFY>
MCF7 NVnGb2s1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIWzbWxKSzVyPUOuOVUhdk1? M{LFUlE5PTZ4MkS2
PC-3 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\wTWM2OD1{LkWxJI5O MnXpNVg2PjZ{NE[=
MMRU MkPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTJwNUegcm0> MkG2NVg2PjZ{NE[=
Hs68 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4eyXWlEPTB;PkGwJI5O MXWxPFU3PjJ2Nh?=
hMSC-001F M3XmVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU[1dlNQUUN3ME2+NVAhdk1? NYjjUmszOTh3Nk[yOFY>

... Click to View More Cell Line Experimental Data

体内研究 与PBS处理的对照组相比,单独使用Erlotinib 和 Romidepsin分别可以对NCI-H1299细胞系的异种移植生长抑制到72% 和 43% ,但是并不具有明显的统计学意义。只有当两种药物联用的时候才会对其生长造成明显的抑制作用,此时生长被抑制到28% [1]。在免疫功能低下的小鼠中,Romidepsin 会抑制皮下NB 异种移植的生长,这种抑制作用具有剂量依赖的特性 。此外, 在NB病人的肿瘤组织中Romidepsin 会诱导某些基因的表达,如 p21 和p75 以及NTRK (TrkA) [2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

+ 展开

HDAC-inhibitory activity:

For the enzyme assay, 10 μL of [3H]acetyl-labeled histones (25,000 cpm/10 μg) are added to 90 μL of the HDAC enzyme fraction extracted from 293T cells overexpressing HDAC1 or HDAC2 in the presence of increasing concentrations of Romidepsin, and the mixture is incubated at 37 °C for 15 minutes. The enzyme reaction is linear for at least 1 hour. The reaction is stopped by the addition of 10 μL of concentrated HCl. The released [3H]acetic acid is extracted with 1 mL of ethylacetate, and 0.9 mL of the solvent layer is taken into 5 mL of aqueous counting scintillant II solution for determination of radioactivity. The IC50 values are determined from at least three independent dose-response curves.
细胞实验:[3]
+ 展开
  • Cell lines: NCI-H1975, NCI-H157, NCI-2882, NCI-H460 和 HCC95 细胞系
  • Concentrations: 1 ng/mL
  • Incubation Time: 72 小时
  • Method: 使用MTS法分析药物敏感性。在96孔平板中每孔接种2×103个细胞(包括NCI-H1975, NCI-H157, NCI-2882, NCI-H460和HCC95) 。24小时后, 在存在或者缺少1 ng/mL Romidepsin的条件下将细胞与不同浓度 (0.01 µM - 250 µM) 的Erlotinib 37°C 孵育72 小时。 MTS 溶液加到每个孔中37°C孵育1小时。利用分光光度计测量490 nm 处的光密度值。每种药物浓度的实验都设置8个复孔并重复两次。基于细胞生存曲线的吸光度值计算药物的半抑制浓度 (IC50) 。
    (Only for Reference)
动物实验:[5]
+ 展开
  • Animal Models: 携带NCI-H1299 细胞的 BALB/c无胸腺裸小鼠
  • Formulation: 用PBS配制
  • Dosages: 1.2 mg/kg
  • Administration: 腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 10 mg/mL (18.49 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用:
2% DMSO+30% PEG 300+5%Tween 80+ddH2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 540.7
化学式

C24H36N4O6S2

CAS号 128517-07-7
稳定性 powder
别名 FR 901228, NSC 630176

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00048334 Completed Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 26, 2002 Phase 1
NCT00094978 Terminated Carcinoma, Small Cell|Carcinoma, Non-Small-Cell Lung|Esophageal Neoplasms|Mesothelioma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 25, 2004 Phase 1
NCT01445340 Terminated Mycosis Fungoides|Cutaneous T-Cell Lymphoma|Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 21, 2007 Phase 1
NCT02616965 Not yet recruiting Cutaneous T-cell Lymphoma (CTCL) Fox Chase Cancer Center|Seattle Genetics, Inc.|Celgene Corporation April 2017 Phase 1
NCT02850016 Recruiting Human Immunodeficiency Virus (HIV) Rockefeller University|University Hospital of Cologne|Aarhus University Hospital December 2016 Phase 2
NCT02757248 Withdrawn PTCL|CTCL Anne Beaven, MD|National Comprehensive Cancer Network|Boehringer Ingelheim|Duke University November 2016 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

相关HDAC产品

Tags: 购买Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide)供应商 | 采购Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide)价格 | Romidepsin (FK228, Depsipeptide)生产 | 订购Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID